SCIENCEDOMAIN *international*
www.sciencedomain.org

SDI Review Form 1.6

PART 1:

Journal Name:	**British Journal of Pharmaceutical Research**
Manuscript Number:	**2013_BJPR_3979**
Title of the Manuscript:	**Formulation, Evaluation and Pharmacokinetics of Flurbiprofen Fast Dissolving Tablets**
Type of the Article	**Research Paper**

General guideline for Peer Review process is available in this link:
(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

- This form has total 7 parts. Kindly note that you should use all the parts of this review form.

SDI Review Form 1.6

PART 2: Review Comments

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments	**1- The manuscript should be revised for both experimental design and English writing.** **2- The work is generally traditional and lacks novelty.**	
Minor REVISION comments	1- The address is " Formulation, Evaluation and Pharmacokinetics of Flurbiprofen Fast Dissolving Tablets" is there any differences between fast dissolve and fast disintegrating tablets? 2- The manuscript should be reviewed for numerous English typo errors. 3- The % symbol must follow every number exploring percentages. 4- The composition of conventional tablet must add to table 1. 5- Sieve number should be added " line 80". 6- The DSC and FTIR should be separated in	

	two paragraphs. 7- Line 165, How many mls samples were taken? 8- Line 199 " average percentage deviation" the listed numbers are not %. 9- Line 108 separate ranges. 10- Line 236, "optimized" you didn`t make factorial design to say optimized.	

Optional/General comments	1- Why pH 1.2 ? 2- Fast dissolve tablets are designed to be taken orally and dissolve fast in the buccal cavity, authors must test the dissolution in simulated saliva for fast dissolve tablets and both simulated gastric and intestinal fluids for conventional tablets. 3- Line 105 , authors test the dispersion in pH 6.8 , why? , Also, the medium can not be said to be simulated saliva ? 4- Line 122, what was the solubililty of FLB in pH 1.2? How many mls of the sink was used? Experiment is not accepted for fast dissolve tablets. pH shift from 6.8 to 1.2 then 7.4 is preferred. 5- Page 11, the difference in dissolution rates between F6 and conventional tablets is high, can authors explain how Ka of both formulations is similar? 1- NOTE: Fast dissolve tablets are designed to be taken orally and dissolve fast in the buccal cavity, authors must test the dissolution in simulated saliva for fast	

	dissolve tablets and both simulated gastric and intestinal fluids for conventional tablets. 2- Patients must be informed to suck tablets or take it in a glass of water after dispersion.	

Note: Anonymous Reviewer